MedTrace Logo

Medical Abortion for Emergency Contraception Failure

NCT00677755 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 394

Last updated 2008-05-16

No results posted yet for this study

Summary

The purpose of this study is to compare the efficacy, safety and acceptability of pre-treatment with mifepristone and misoprostol compared to misoprostol alone in the medical termination of pregnancy by mifepristone EC failure.

Conditions

  • Emergency Contraception
  • Abortion, Induced

Interventions

DRUG

mifepristone combined misoprostol

women received a single dose of mifepristone (Mifepristone tablets; Xianju Pharmacy, Zhejiang, China) 200mg orally on day 1, and then returned to the clinic on day 3 and were given misoprostol (Cytotec tables; Searle,A Division of Monsanto.P.L.C, England )0.8mg orally

DRUG

misoprostol alone protocol

patients were only administered 0.8 mg of misoprostol orally on day 3.

Sponsors & Collaborators

  • Taizhou Hospital

    lead OTHER

Principal Investigators

  • YiYang Zhu, MD · Centra for Reproductive Medicine of Taizhou hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
16 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-10-31
Primary Completion
2007-09-30
Completion
2007-11-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00677755 on ClinicalTrials.gov